Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/20/2017 04/21/2017 04/24/2017 04/25/2017 04/26/2017 Date
6.97(c) 7.09(c) 7.31(c) 7.63(c) 7.93(c) Last
1 744 833 1 464 754 1 171 898 1 479 333 1 748 856 Volume
+7.56% +1.72% +3.10% +4.38% +3.93% Change
More quotes
Financials ($)
Sales 2017 127 M
EBIT 2017 -57,5 M
Net income 2017 -63,0 M
Debt 2017 -
Yield 2017 -
Sales 2018 135 M
EBIT 2018 -35,5 M
Net income 2018 -39,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 4,82x
Capi. / Sales2018 4,56x
Capitalization 614 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma.It operates through... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
04/25 SPECTRUM PHARMACEUTICALS : Announces First Quarter 2017 Financial Results Teleco..
04/04 SPECTRUM PHARMACEUTICALS : Highlights Preclinical Data of ROLONTIS™ (eflap..
03/31 SPECTRUM PHARMACEUTICALS : Highlights Three Abstracts on ROLONTIS™ (eflape..
03/30 SPECTRUM PHARMACEUTICALS : Announces Initiation of a Phase 2 Trial of Poziotinib..
03/14 SPECTRUM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
03/10 SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8..
03/08 SPECTRUM PHARMACEUTICALS : Pharma reports 4Q loss
03/08 SPECTRUM PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
03/08 SPECTRUM PHARMACEUTICALS : Reports Fourth Quarter 2016 and Full Year 2016 Financ..
03/01 SPECTRUM PHARMACEUTICALS : Announces Fourth Quarter and Full Year 2016 Financial..
More news
Sector news : Biotechnology & Medical Research - NEC
12:35a AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
12:46aWant the latest analyst ratings on $CASY $BDC $TKR $SPPI $ARII? Get Them Deli.. 
04/21$SPPI pretty chart just took out yest highs 
04/17CASI Pharmaceuticals's buy rating reiterated at Maxim Group. $4.00 PT.  
04/14BRIEF-CASI Pharmaceuticals reports on enrollment status of ENMD-2076 phase 2 .. 
04/14CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study .. 
More tweets
Qtime:22
News from SeekingAlpha
03/30 Mid-stage study launched assessing Spectrum Pharma's poziotinib in certain lu..
03/09 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
03/08 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q4 2016 Results - Ea..
03/08 After Hours Gainers / Losers
03/08 Spectrum Pharma Q4 top line down 30%, net loss widens; shares down 15% after ..
Advertisement
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 9,83 $
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph W. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICA..72.23%614
INCYTE CORPORATION22.75%25 448
QUINTILES IMS HOLDINGS..8.68%19 499
LONZA GROUP AG19.57%11 845
CELLTRION, INC.--.--%9 687
SEATTLE GENETICS, INC.26.59%9 527
More Results